Dellon ES, et al. - An open-label extension study of a 12-week, multicenter, randomized, double-blind, placebo-controlled trial was performed to ascertain the safety and efficacy of budesonide oral suspension (BOS) maintenance therapy in patients with eosinophilic esophagitis (EoE). For the purpose of this investigation, subjects with EoE (11–40 years old) who performed double-blind BOS (n=45) or placebo therapy (n=37) received 24 weeks’ open-label BOS (2.0 mg once daily for 12 weeks, with optional dose increase [1.5–2.0 mg twice daily] for 12 weeks thereafter). Researchers observed that BOS was well tolerated and drug-related adverse events were uncommon in an open-label extension study of patients with EoE. Findings revealed that BOS maintained a histologic response in some initial responders however few initial non-responders had a response.